Brokerages Set Glaukos Co. (NYSE:GKOS) PT at $151.08

Shares of Glaukos Co. (NYSE:GKOS) have earned a consensus recommendation of “Moderate Buy” from the thirteen analysts that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, eleven have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $159.42.

Several equities analysts recently weighed in on the stock. Stephens raised shares of Glaukos to a “strong-buy” rating in a research note on Monday, December 2nd. BTIG Research raised their target price on shares of Glaukos from $140.00 to $149.00 and gave the company a “buy” rating in a research note on Tuesday, November 26th. Morgan Stanley cut shares of Glaukos from an “equal weight” rating to an “underweight” rating and set a $120.00 target price for the company. in a research note on Monday, December 2nd. Truist Financial raised their target price on shares of Glaukos from $152.00 to $185.00 and gave the company a “buy” rating in a research note on Wednesday, December 18th. Finally, Mizuho raised shares of Glaukos from a “neutral” rating to an “outperform” rating and raised their target price for the company from $140.00 to $200.00 in a research note on Wednesday.

Glaukos Price Performance

NYSE GKOS opened at $161.30 on Thursday. The company has a quick ratio of 4.71, a current ratio of 5.54 and a debt-to-equity ratio of 0.19. Glaukos has a 12-month low of $83.90 and a 12-month high of $163.71. The company has a market capitalization of $8.89 billion, a PE ratio of -53.41 and a beta of 1.04. The firm’s 50 day moving average is $152.65 and its 200-day moving average is $139.03.

Insider Activity

In other news, Director Gilbert H. Kliman sold 2,000 shares of the business’s stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $144.01, for a total value of $288,020.00. Following the completion of the sale, the director now owns 32,336 shares of the company’s stock, valued at approximately $4,656,707.36. The trade was a 5.82 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Tomas Navratil sold 3,416 shares of the business’s stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $147.14, for a total transaction of $502,630.24. Following the completion of the sale, the insider now directly owns 72,437 shares of the company’s stock, valued at approximately $10,658,380.18. The trade was a 4.50 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 18,744 shares of company stock valued at $2,792,151. 6.40% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of GKOS. Wellington Management Group LLP raised its stake in Glaukos by 294.5% in the third quarter. Wellington Management Group LLP now owns 2,183,766 shares of the medical instruments supplier’s stock valued at $284,501,000 after purchasing an additional 1,630,270 shares in the last quarter. William Blair Investment Management LLC acquired a new position in Glaukos in the fourth quarter valued at about $121,390,000. Alliancebernstein L.P. raised its stake in Glaukos by 1,235.4% in the fourth quarter. Alliancebernstein L.P. now owns 816,153 shares of the medical instruments supplier’s stock valued at $122,374,000 after purchasing an additional 755,035 shares in the last quarter. Norges Bank acquired a new position in Glaukos in the fourth quarter valued at about $84,490,000. Finally, Charles Schwab Investment Management Inc. raised its stake in Glaukos by 47.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 641,761 shares of the medical instruments supplier’s stock valued at $83,609,000 after purchasing an additional 207,338 shares in the last quarter. Institutional investors and hedge funds own 99.04% of the company’s stock.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.